Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab
Clinical journal of oncology nursing2019Vol. 23(4), pp. E73–E80
Citations Over Time
Abstract
Mogamulizumab is an effective treatment for adult patients with relapsed or refractory MF/SS-type CTCL who have received at least one prior systemic therapy. Infusion reactions and drug eruptions require prompt diagnosis and treatment.
Related Papers
- → Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology(2013)86 cited
- → Mycosis Fungoides in Skin of Color(2022)2 cited
- → Cutaneous T-cell lymphoma (mycosis fungoides)(1996)63 cited
- → Cutaneous T-cell lymphoma (mycosis fungoides)(1996)9 cited
- → Inflammatory Precursors of Mycosis Fungoides(1994)2 cited